ScalmiBio

San Carlos, United States Founded: 2016 • Age: 10 yrs Acquired By ALX Oncology
Antibodies are developed to minimize cancer drug side effects.

About ScalmiBio

ScalmiBio is a company based in San Carlos (United States) founded in 2016 by Marija Vrljic was acquired by ALX Oncology in October 2021.. ScalmiBio operates in a competitive market with competitors including Osmol Therapeutics, Secretome Therapeutics, Cell Source, Egetis and Metys Pharmaceuticals, among others.

  • Headquarter San Carlos, United States
  • Founders Marija Vrljic
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $299.96 K (USD), Grant

    Mar 11, 2019

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    ALX Oncology

    (Oct 07, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of ScalmiBio

  • Total Funding
  • Total Rounds 1
  • Last Round Grant — $299,957
  • First Round

    (11 Mar 2019)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2019 Amount Grant - ScalmiBio Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ScalmiBio

ScalmiBio has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include ALX Oncology and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
ALX Oncology is focused on advancing cancer treatment therapies.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ScalmiBio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ScalmiBio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Scalmibio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ScalmiBio

ScalmiBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Osmol Therapeutics, Secretome Therapeutics, Cell Source, Egetis and Metys Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Treatments for chemotherapy-induced peripheral neuropathy are developed.
domain founded_year HQ Location
Cell-based therapies for multiple diseases are developed.
domain founded_year HQ Location
Cell therapy treatments for transplantation, cancer treatment and reversal of vital organ disease
domain founded_year HQ Location
Therapeutics for rare and other diseases are developed.
domain founded_year HQ Location
Drugs for chemotherapy-induced peripheral neuropathy and CNS disorders are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Scalmibio

ALX Oncology’s Acquisition of ScalmiBio
Globallegalchronicle4 years ago

Frequently Asked Questions about ScalmiBio

When was ScalmiBio founded?

ScalmiBio was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is ScalmiBio located?

ScalmiBio is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.

What does ScalmiBio do?

ScalmiBio was founded in 2016 and is based in San Carlos, United States. Operations focus on the biotechnology sector, particularly oncology therapeutics. The SHIELD platform technology is utilized to convert therapeutic antibodies into prodrugs activated specifically within tumors. This approach allows for higher dosing of cancer treatments and supports multi-target combination therapies, aiming to reduce systemic side effects.

Who are the top competitors of ScalmiBio?

ScalmiBio's top competitors include Secretome Therapeutics, Osmol Therapeutics and Cell Source.

Who are ScalmiBio's investors?

ScalmiBio has 2 investors. Key investors include ALX Oncology, and HHS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available